Skip to main content
. 2022 Mar 21;52(5):724–739. doi: 10.1111/imj.15698

Table 3.

Comorbidities among survivors and non‐survivors, along with risk ratio (including log‐transformed)

Comorbidities No. studies Mortality for patients with each comorbidity, % (n/N) Mortality for patients without each comorbidity, % (n/N) Log of risk ratio (95% CI) Risk ratio (95% CI) I 2
Dementia 12 44.8 (657/1466) 28.6 (2496/8735) 0.33 (0.20, 0.46) 1.39 (1.22, 1.58) 70.7%
Chronic kidney disease 13 39.2 (1041/2658) 20.6 (4358/21 131) 0.21 (0.11, 0.30) 1.23 (1.12, 1.35) 55.9%
Smoking 6 35.6 (580/1628) 32.6 (1186/3635) 0.07 (0.02, 0.12) 1.07 (1.02, 1.13) 6.4%
Heart failure 8 32.6 (956/2931) 16.4 (2685/16 398) 0.28 (0.11, 0.46) 1.22 (1.08, 1.36) 72.7%
Cardiovascular disease 19 29.7 (3627/12 214) 21.5 (4323/20 153) 0.25 (0.18, 0.33) 1.28 (1.07, 1.54) 89.2%
Cerebrovascular accident 9 29.4 (1172/3990) 20.2 (3714/18 409) 0.25 (0.07, 0.43) 1.28 (1.20, 1.39) 83.3%
Hypertension 20 24.3 (4733/19 461) 22.2 (1635/7358) 0.12 (0.07, 0.17) 1.13 (1.07, 1.19) 76.4%
Diabetes mellitus 21 27.6 (3054/11 084) 24.2 (5197/21 461) 0.10 (0.05, 0.14) 1.11 (1.05, 1.15) 62.5%
Chronic respiratory disease 20 24.6 (2347/9528) 21.5 (3888/18 121) 0.04 (0.03, 0.07) 1.02 (0.97, 1.07) 64.3%
Obesity 9 26.7 (556/2079) 31.9 (2402/7528) 0.06 (−0.12, 0.012) 0.94 (0.89, 1.01) 49.2%

Respiratory diseases include a composite of asthma, chronic obstructive pulmonary disease and pulmonary fibrosis. Bold values are statistically significant.